Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere Clinical Trials
2 recruiting trials for Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere. Eligibility criteria explained in plain English.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases
The RMD-mILDer trial is a home monitoring strategy trial aiming to improve management of interstitial lung disease related to rheumatic diseases applying eHealth technology. It...
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice — always talk to your doctor about clinical trial participation.